Oryzon Genomics SA
MAD:ORY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Reinsurance Group of America Inc
NYSE:RGA
|
US |
Oryzon Genomics SA
Non-Reccuring Items
Oryzon Genomics SA
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oryzon Genomics SA
MAD:ORY
|
Non-Reccuring Items
-€2.4k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
35%
|
|
|
Grifols SA
MAD:GRF
|
Non-Reccuring Items
-€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharma Mar SA
MAD:PHM
|
Non-Reccuring Items
€754k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oryzon Genomics SA
Glance View
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
See Also
What is Oryzon Genomics SA's Non-Reccuring Items?
Non-Reccuring Items
-2.4k
EUR
Based on the financial report for Dec 31, 2025, Oryzon Genomics SA's Non-Reccuring Items amounts to -2.4k EUR.
What is Oryzon Genomics SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 10Y
35%
